Cyaki Osamu
Department of obstetrics and gynecology, Yokohama City University School of Medicine.
Clin Calcium. 2004 Oct;14(10):39-46.
The change in BMD is poor predictor of vertebral fracture risk after Raloxifene treatment, whereas bone turnover markers were significantly associated with fracture risk. The percent change in osteocalcin (OC) was better able to predict the reduction in vertebral fracture risk than the percent change in femoral neck BMD in patients treated with Raloxifene in MORE study.
雷洛昔芬治疗后，骨密度变化对椎体骨折风险的预测能力较差，而骨转换标志物与骨折风险显著相关。在MORE研究中，接受雷洛昔芬治疗的患者中，骨钙素（OC）的百分比变化比股骨颈骨密度的百分比变化更能预测椎体骨折风险的降低。
Zotero 插件